JP2018521056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521056A5 JP2018521056A5 JP2017568056A JP2017568056A JP2018521056A5 JP 2018521056 A5 JP2018521056 A5 JP 2018521056A5 JP 2017568056 A JP2017568056 A JP 2017568056A JP 2017568056 A JP2017568056 A JP 2017568056A JP 2018521056 A5 JP2018521056 A5 JP 2018521056A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- acceptable salt
- prevention
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 **CNc1n[o]nc1C(*NO)Nc(cc1Br)ccc1F Chemical compound **CNc1n[o]nc1C(*NO)Nc(cc1Br)ccc1F 0.000 description 10
- ASKFAJSXYFJELQ-UHFFFAOYSA-N C=[Br]c1cc(NC(c2n[o]nc2NCCNC(c(cc2)cc3c2C=COB3O)=O)NO)ccc1F Chemical compound C=[Br]c1cc(NC(c2n[o]nc2NCCNC(c(cc2)cc3c2C=COB3O)=O)NO)ccc1F ASKFAJSXYFJELQ-UHFFFAOYSA-N 0.000 description 2
- RIYRBWHNQTZMBR-UHFFFAOYSA-N CC(C)C(C1=CC=C(CCOB2O)C2C1)=O Chemical compound CC(C)C(C1=CC=C(CCOB2O)C2C1)=O RIYRBWHNQTZMBR-UHFFFAOYSA-N 0.000 description 2
- DNXAZITYJYNQPQ-UHFFFAOYSA-N CC(C)C(c1cccc2c1B(O)OC2)=O Chemical compound CC(C)C(c1cccc2c1B(O)OC2)=O DNXAZITYJYNQPQ-UHFFFAOYSA-N 0.000 description 2
- IZBNWPJOYYKSFJ-UHFFFAOYSA-N CC(C)C(c1cccc2c1B(O)OC=C2)=C Chemical compound CC(C)C(c1cccc2c1B(O)OC=C2)=C IZBNWPJOYYKSFJ-UHFFFAOYSA-N 0.000 description 2
- KAACQIWZUMBEBJ-UHFFFAOYSA-N CC(C)Cc1c(COB2O)c2ccc1 Chemical compound CC(C)Cc1c(COB2O)c2ccc1 KAACQIWZUMBEBJ-UHFFFAOYSA-N 0.000 description 2
- NGCVQDIQHBKURP-UHFFFAOYSA-N OB1OC=Cc2cccc(C(NCCNc3n[o]nc3C(Nc(cc3Br)ccc3F)NO)=O)c12 Chemical compound OB1OC=Cc2cccc(C(NCCNc3n[o]nc3C(Nc(cc3Br)ccc3F)NO)=O)c12 NGCVQDIQHBKURP-UHFFFAOYSA-N 0.000 description 2
- OYXGRSQLNLZJRZ-UHFFFAOYSA-N OB1OCCc2c1c(C=O)ccc2 Chemical compound OB1OCCc2c1c(C=O)ccc2 OYXGRSQLNLZJRZ-UHFFFAOYSA-N 0.000 description 2
- QWIUWMGHWXDMAA-UHFFFAOYSA-N OB1OCCc2cccc(C(NCCNc3n[o]nc3C(CNO)Nc(cc3Br)ccc3F)=O)c12 Chemical compound OB1OCCc2cccc(C(NCCNc3n[o]nc3C(CNO)Nc(cc3Br)ccc3F)=O)c12 QWIUWMGHWXDMAA-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187937P | 2015-07-02 | 2015-07-02 | |
| US62/187,937 | 2015-07-02 | ||
| PCT/IB2016/053947 WO2017002078A1 (en) | 2015-07-02 | 2016-06-30 | Inhibitors of indoleamine 2,3-dioxygenase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521056A JP2018521056A (ja) | 2018-08-02 |
| JP2018521056A5 true JP2018521056A5 (enExample) | 2019-05-09 |
| JP6654208B2 JP6654208B2 (ja) | 2020-02-26 |
Family
ID=56363880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568056A Expired - Fee Related JP6654208B2 (ja) | 2015-07-02 | 2016-06-30 | インドールアミン２，３−ジオキシゲナーゼの阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10239894B2 (enExample) |
| EP (1) | EP3317287B1 (enExample) |
| JP (1) | JP6654208B2 (enExample) |
| KR (1) | KR20180022988A (enExample) |
| CN (1) | CN107709338A (enExample) |
| AU (1) | AU2016285483B2 (enExample) |
| BR (1) | BR112017028456A2 (enExample) |
| CA (1) | CA2990335A1 (enExample) |
| ES (1) | ES2752455T3 (enExample) |
| RU (1) | RU2018101431A (enExample) |
| WO (1) | WO2017002078A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108530444B (zh) * | 2018-06-11 | 2021-08-24 | 药康众拓(江苏)医药科技有限公司 | 一种新型nampt和ido双重抑制剂及其制备方法和医药用途 |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| FI3873903T3 (fi) | 2018-10-31 | 2024-03-26 | Gilead Sciences Inc | Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| CN110156629A (zh) * | 2019-05-30 | 2019-08-23 | 广州药本君安医药科技股份有限公司 | 丙卡巴肼的合成方法 |
| EP4301358A2 (en) | 2021-03-05 | 2024-01-10 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| WO2025119216A1 (zh) * | 2023-12-04 | 2025-06-12 | 珠海联邦制药股份有限公司 | 硼酸类β-内酰胺酶抑制剂及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| NZ528270A (en) | 2001-03-19 | 2005-10-28 | Ono Pharmaceutical Co | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
| RS52711B (sr) * | 2005-05-10 | 2013-08-30 | Incyte Corporation | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih |
| BRPI0614995A2 (pt) | 2005-08-31 | 2010-01-12 | Celgene Corp | composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de uma quantidade terapêutica ou profilaticamente eficaz de um composto ou um sal, solvato ou estereoisemero farmaceuticamente aceitável do mesmo, e, forma de dosagem unitária única |
| PL2315756T3 (pl) * | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
| TW201221131A (en) * | 2010-11-18 | 2012-06-01 | Glaxo Group Ltd | Compounds |
| EP2911669B1 (en) | 2012-10-26 | 2024-04-10 | The University of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
-
2016
- 2016-06-30 BR BR112017028456A patent/BR112017028456A2/pt not_active Application Discontinuation
- 2016-06-30 CA CA2990335A patent/CA2990335A1/en not_active Abandoned
- 2016-06-30 CN CN201680039221.7A patent/CN107709338A/zh active Pending
- 2016-06-30 KR KR1020187003254A patent/KR20180022988A/ko not_active Withdrawn
- 2016-06-30 EP EP16735943.9A patent/EP3317287B1/en active Active
- 2016-06-30 RU RU2018101431A patent/RU2018101431A/ru not_active Application Discontinuation
- 2016-06-30 AU AU2016285483A patent/AU2016285483B2/en not_active Ceased
- 2016-06-30 JP JP2017568056A patent/JP6654208B2/ja not_active Expired - Fee Related
- 2016-06-30 WO PCT/IB2016/053947 patent/WO2017002078A1/en not_active Ceased
- 2016-06-30 ES ES16735943T patent/ES2752455T3/es active Active
- 2016-06-30 US US15/578,861 patent/US10239894B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521056A5 (enExample) | ||
| JP2017533930A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2018531941A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2016503793A5 (enExample) | ||
| EP4458348A3 (en) | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | |
| JP2020500916A5 (enExample) | ||
| JP2012504133A5 (enExample) | ||
| JP2013507423A5 (enExample) | ||
| JP2017518334A5 (enExample) | ||
| EP4616908A3 (en) | Oxysterols and methods of use thereof | |
| JP2013545785A5 (enExample) | ||
| JP2017524025A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2015504081A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| JP2012092103A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| JP2016513130A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2013521295A5 (enExample) | ||
| JP2014500861A5 (enExample) | ||
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| JP2016505614A5 (enExample) |